MedTrace Logo

Evaluate IMG-007 in Healthy Participants

NCT05353972 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-06-28

No results posted yet for this study

Summary

This first in human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK)), and immunogenicity of a single ascending dose of IMG-007 in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

IMG-007 or placebo

intravenously administered

Sponsors & Collaborators

  • Inmagene LLC

    lead INDUSTRY

Principal Investigators

  • Peter Schrader · Linear

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05353972 on ClinicalTrials.gov